Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue

Competitive Landscape Also Changing

Executive Summary

The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.

You may also be interested in...



China 'No' For Celgene's Paclitaxel A Major Blow To BeiGene

After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for  Celgene's Abraxane to supply China.

3D Med, Alphamab Get First SubQ Immuno-Oncology Approval, In China

A landmark approval and domestic tie-up in China mark the fast innovation that is shaping the country’s health sector.

Pharma Will Need To Embrace More Inward-Looking China

The world’s second-largest economy is fast moving away from reforms and open to a "dual circulation" model, focusing on domestic market consumption while reducing export-driven production. Executives and investors shared views at a conference on whether multinational pharma firms are still welcome in China and what opportunities may lie in the drastic policy shift.

Topics

Related Companies

UsernamePublicRestriction

Register

SC145237

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel